EDEkaterina A. Dobreva

Ekaterina A. Dobreva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ekaterina A. Dobreva has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Rare Forms of Hereditary Hypoparathyroidism: Delayed Diagnosis Due To Atypical Disease Onset

    by Ekaterina Bibik, Kamila Meirambek, Rustam Salimkhanov, Anna Eremkina, Sergey Popov, Ekaterina Dobreva, Marina Yukina, Ekaterina Troshina, Natalia Mokrysheva

    Background: Hereditary hypoparathyroidism (hypoPT) is a rare endocrine disorder caused by absent or insufficient parathyroid hormone secretion. Genetic forms are uncommon and frequently underdiagnosed, particularly when clinical onset is atypical.Purpose: We present three cases of genetic hypoPT caused by CASR, GNA11, and GATA3 mutations, highlighting diagnostic challenges and management approaches.Methods: Clinical data, biochemical results, and genetic findings were collected for three female patients with early-onset, nonsurgical hypoPT. Each case was evaluated for presenting symptoms, comorbidities, treatment responses, and outcomes. Relevant literature and guidelines were reviewed for context and management recommendations.Results: All patients exhibited chronic hypocalcemia, hyperphosphatemia, and low PTH without prior neck surgery. Initial manifestations were atypical, delaying diagnosis until adolescence or adulthood. Case 1 (CASR mutation) presented with seizure-like episodes misdiagnosed as epilepsy, and partial response to calcium–vitamin D therapy. Case 2 (GNA11 mutation) showed Raynaud’s phenomenon, dermatologic symptoms, and treatment intolerance without nephrocalcinosis. Case 3 (GATA3 mutation) had early deafness, later renal impairment, and fluctuating calcium levels. Genetic testing confirmed pathogenic variants, and individualized management with active vitamin D analogs achieved partial biochemical control. All patients remain under multidisciplinary follow-up with stabilization of neurological complications and monitoring of renal status. Conclusion: Genetic causes of hypoPT should be suspected in patients with early-onset or atypical presentations in the absence of neck surgery. Timely genetic testing confirms the diagnosis and determines personalized therapy. Management requires careful titration of calcium and active vitamin D to avoid complications and may benefit from emerging treatments (long-acting PTH analogs). Early recognition and tailored interventions can improve patient outcomes and quality of life.

  • Primary Hyperparathyroidism and Cardiovascular Disease

    by E. A. Dobreva, E. V. Tarasova, A. M. Gorbacheva, E. E. Bibik, I. Z. Bondarenko, N. G. Mokrysheva

    Cardiovascular diseases (CVDs) have long been the leading cause of mortality and morbidity worldwide. It has been demonstrated that disturbances in calcium-phosphate metabolism, particularly primary hyperparathyroidism (PHPT), may further contribute to their development and progression. Despite the established association between PHPT and CVD, many aspects of this relationship remain insufficiently explored. The state of the cardiovascular system plays a decisive role in assessing patient mortality; however, there are currently no clear predictors of CVD development in PHPT. At present, cardiovascular pathology is not listed among the absolute indications for surgical treatment of parathyroid gland disorders. Nevertheless, given the high prevalence of hypertension and other CVDs, the updated national guidelines on PHPT now include a mandatory cardiology consultation for all patients to assess cardiovascular health and prepare for potential surgery. The aim of this article is to review recent research on the impact of PHPT on the cardiovascular system, analyse the underlying pathogenic mechanisms, and discuss diagnostic and treatment strategies for this patient group. A comprehensive assessment of cardiovascular changes — with an emphasis on their pathogenetic basis — is essential for improving both the quality and longevity of life in the population.

  • Open Access

    Genetic Landscape of Obesity in Children: Research Advances and Prospects

    by Rita Khusainova, Ildar Minniakhmetov, Olga Vasyukova, Bulat Yalaev, Ramil Salakhov, Darya Kopytina, Raisat Guseinova, Ekaterina Dobreva, Galina Melnichenko, Ivan Dedov, et al.

    Obesity is a chronic metabolic disease characterized by excessive accumulation or uneven distribution of fat in the body, which poses a serious threat to health. Obesity significantly increases the risk of developing сonditions such as type 2 diabetes, coronary heart disease, hypertension, obstructive sleep apnea, and some types of cancer. The prevalence of obesity, especially in childhood, has increased significantly worldwide over the past few decades. The World Health Organization predicts that 250 million children and adolescents aged 5–19 years will be obese by 2030, which indicates a global problem with far‐reaching consequences. Advances in genomic technologies have led to the identification of multiple genetic loci associated with the disease ranging from severe cases with early onset to common multifactorial polygenic forms. Epigenetic changes driven by dietary and lifestyle factors are now recognized as crucial contributors to obesity. These modifications can alter gene expression and thereby link environmental influences to the observable clinical features of the disease. Significant progress has been made in deciphering the genetic architecture of obesity, particularly in pediatric populations. However, further advancement requires integrative multiomics analyses that encompass genomic, epigenomic, transcriptomic, proteomic, metabolomic, and microbiome data. To better understand the complex molecular underpinnings and clinical variability of obesity, researchers are increasingly applying methods from machine learning and artificial intelligence. These technologies help analyze large‐scale genomic and phenotypic datasets, allowing for the identification of biological pathways involved in weight regulation. In the future, this may support the design of individualized diagnostic tools and targeted treatment plans that reflect a patient’s genetic profile, lifestyle, and environmental exposures. To implement the principles of personalized and precision medicine in the treatment of obesity, it is crucial to identify risk profiles by assessing multiple contributing factors. This approach not only enables the prediction of an individual’s risk of obesity and its associated diseases but also facilitates the optimization of treatment based on the patient’s genetic profile. This study provides a comprehensive overview of the current understanding of childhood obesity, including its prevalence, genetic determinants, and pathophysiological mechanisms. It highlights the contribution of genetic factors to hereditary and syndromic forms, the role of gene–environment interactions (including nutrition and environmental pollutants), and the influence of epigenetic modifications on metabolic disturbances associated with polygenic obesity.


  • Open Access

    Pathology of carbohydrate metabolism in primary hyperparathyroidism: epidemiological and clinical characteristics

    by E. E. Bibik, E. A. Dobreva, A. K. Eremkina, N. G. Mokrysheva

    Primary hyperparathyroidism (PHPT) is characterized by disorders of not only mineral metabolism, but also other kinds of the human metabolism. Due to the increased frequency of cardiovascular risk factors among patients with PHPT, the study of the carbohydrate metabolism pathology in this cohort of patients will allow developing optimal approaches to their timely diagnosis and treatment.Aim. To determine the frequency and describe the clinical features of carbohydrate metabolism disorders in patients with PHPT.Material and methods. A single-center retrospective study of adults with PHPT was carried out with an assessment of the main parameters of mineral and carbohydrate metabolism before surgical treatment of the disease. The exclusion criteria were the absence of PHPT remission or a recurrence of the disease after parathyroidectomy; pregnancy, lactation. The frequency of various disorders of carbohydrate metabolism in PHPT, the comparative characteristics of mineral parameters in patients with and without them, as well as the severity of type 2 diabetes mellitus in PHPT were determined. In addition, potential relationships between the parameters of various types of metabolism have been studied.Results. The study was based on a clinical information of 367 patients with PHPT, most of whom had a symptomatic form of the disease. The overall incidence of prediabetic disorders was 4,9% (95% CI: 3-8). Type 2 diabetes mellitus was previously diagnosed in 45 patients (12%, 95% CI: 9-16), there were no cases of first diagnosed diabetes mellitus. Individuals with impaired carbohydrate metabolism had a statistically significantly higher body mass index and lower values of osteocalcin (27,2 [24,2; 30,4] kg/m2 vs 32,7 [28,1; 39,4 kg/m2 and 48,1 [34; 76,3] ng/mL vs 33,1 [20,8; 51,8] ng/mL, respectively, for all parameters pConclusion. Among patients with PHPT, type 2 diabetes mellitus is more common than in the general population. The likely reason of this may be insulin resistance, that can be caused by the effects of bone metabolites, primarily osteocalcin. In most cases, metformin makes it possible to achieve compensation for diabetes mellitus in PHPT.

  • Open Access

    Primary hyperparathyroidism in young patients is associated with metabolic disorders: a prospective comparative study

    by Ekaterina E. Bibik, Ekaterina A. Dobreva, Alina R. Elfimova, Anastasiia P. Miliutina, Anna K. Eremkina, Anna M. Gorbacheva, Julia A. Krupinova, Ekaterina O. Koksharova, Igor A. Sklyanik, Alexander Y. Mayorov, et al.

    Background: Components of metabolic syndrome can be observed in patients with primary hyperparathyroidism (PHPT). The link between these disorders remains unclear due to the lack of relevant experimental models and the heterogeneity of examined groups. The effect of surgery on metabolic abnormalities is also controversial. We conducted a comprehensive assessment of metabolic parameters in young patients with PHPT. Methods: One-center prospective comparative study was carried out. The participants underwent a complex biochemical and hormonal examination, a hyperinsulinemic euglycemic and hyperglycemic clamps, a bioelectrical impedance analysis of the body composition before and 13 months after parathyroidectomy compared to sex-, age- and body mass index matched healthy volunteers. Results: 45.8% of patients (n = 24) had excessive visceral fat. Insulin resistance was detected in 54.2% of cases. PHPT patients had higher serum triglycerides, lower M-value and higher C-peptide and insulin levels in both phases of insulin secretion compared to the control group (p < 0.05 for all parameters). There were tendencies to decreased fasting glucose (p = 0.031), uric acid (p = 0.044) and insulin levels of the second secretion phase (p = 0.039) after surgery, but no statistically significant changes of lipid profile and M-value as well as body composition were revealed. We obtained negative correlations between percent body fat and osteocalcin and magnesium levels in patients before surgery. Conclusion: PHPT is associated with insulin resistance that is the main risk factor of serious metabolic disorders. Surgery may potentially improve carbohydrate and purine metabolism.


  • Open Access

    Soluble endoglin as a perspective marker of endothelial dysfunction in patients with primary hyperparathyroidism: a pilot study

    by A. M. Gorbacheva, E. E. Bibik, E. A. Dobreva, A. R. Elfimova, A. K. Eremkina, N. G. Mokrysheva

    BACKGROUND: Primary hyperparathyroidism (PHPT), one of the most common endocrine pathologies, is associated with a higher incidence of cardiovascular diseases, in particular, those caused by endothelial dysfunction. Evaluation of endothelial dysfunction in patients with PHPT will predict the development of cardiovascular pathology and determine the optimal tactics for PHPT management.AIM: To evaluate the concentration of soluble endoglin and photoplethysmographic parameters as potential markers of endothelial dysfunction in patients with PHPT.MATERIALS AND METHODS: A single-center interventional single-stage study was carried out. 2 groups were formed. The first group included 50 patients with verified PHPT who did not have cardiovascular or other concomitant somatic pathologies in anamnesis. The comparison group included 21 healthy volunteers comparable in sex and age. All participants underwent a biochemical blood test (total calcium, ionized, albumin, lipidogram, urea, uricacid, glucose, creatinine, alkaline phosphatase), parathyroid hormone, 25 (OH) D and endoglin concentrations were evaluated. In addition, echocardiography, ultrasound of the brachiocephalic arteries and arteries of the lower extremities, as well as photoplethysmography were performed.RESULTS: The groups differed in mineral parameters associated with PHPT; no differences were found in parameters of lipid, uric acid and carbohydrate metabolism. Serum levels of endoglin were lower in PHPT patients (p=0.002). We found a negative correlation between the concentration of albumin-corrected calcium and PTH with endoglin (r1=-0.370, p1=0.003 and r2=-0.475, p2CONCLUSION: The serum level of soluble endoglin is lower in patients with PHPT than in healthy volunteers, negatively correlates with calcium and PTH concentrations and positively with serum phosphorus concentrations. Further studies will make it possible to establish the pathogenetic mechanism of the identified relationships and evaluate the role of endoglin as a potential predictor of cardiovascular pathology in PHPT population.


  • Open Access

    Changes of metabolic parameters in patients with primary hyperparathyroidism of different age groups

    by E. E. Bibik, A. M. Gorbacheva, E. A. Dobreva, A. R. Elfimova, A. K. Eremkina, N. G. Mokrysheva

    BACKGROUND: Studies have shown a high incidence of metabolic disorders and cardiovascular diseases in patients with primary hyperparathyroidism (PHPT). PHPT is usually diagnosed in people of age over 50 years and therefore age-associated changes of metabolism should be excluded. Researching predictors of cardiovascular pathology contributes to choosing optimal approaches to personalized patient management.AIM: To determine the features of metabolic disorders in patients of various age groups with confirmed active stage of PHPT.MATERIALS AND METHODS: A single-center observational retrospective comparative study of patients with active PHPT at the age of 18-49 years (Group 1, n=66) and over 50 years (Group 2, n=290) was carried out. The exclusion criteria for both groups were: persistent PHPT or recurrence after surgical treatment of the disease in history; clinical/genetically confirmed multiple endocrine neoplasia syndrome; for Group 1 — pregnancy, lactation. The assessment of laboratory parameters of mineral, carbohydrate, fat and purine metabolism obtained during a hospital examination was carried out, the frequencies of various metabolic disorders were determined and compared between age groups.RESULTS: There were no significant differences in parathyroid hormone and serum calcium levels between age groups, however, there were more severe hypercalciuria, a tendency to active bone metabolism and lower vitamin D level in Group 1. Patients of Group 2 had statistically significantly lower glomerular filtration rate and a higher frequency of bone complications. In the same group glycaemia and triglycerides levels were higher (the latter difference has the level of a statistical tendency). These patients also had a higher body mass index and, as a result, a higher incidence of obesity (37% vs 20%, p=0.006) and diabetes mellitus type 2 (12.5% vs 3%, p=0.013). At the same time, patients did not significantly differ in the rates of hypercholesterolemia (62% in Group 1 vs 70% in Group 2, p=0.228), hypertriglyceridemia (27% vs 32%, p=0.433) and hyperuricemia (42% vs 50%, p=0.302), significantly exceeding similar indicators in the general Russian population.CONCLUSION: Carbohydrate disorders are more often observed in patients older than 50 years, providing an increased prevalence of diabetes mellitus type 2 among patients with PHPT compared with the general population. The high incidence of various types of dyslipidemia and hyperuricemia in the primary parathyroid pathology has no age specific features. Thereby these disorders are significant risk factors of cardiovascular diseases, even in young people with PHPT.

  • Different treatment strategies in primary hyperparathyroidism during pregnancy

    by A. Eremkina, E. Bibik, S. Mirnaya, J. Krupinova, A. Gorbacheva, E. Dobreva, N. Mokrysheva

    Purpose Primary hyperparathyroidism (PHPT) in pregnancy is rare enough and can be unrecognized because of nonspecific symptoms in most cases, but life-threatening complications for mother, fetus and neonate also occurs. PHPT requires frequent monitoring of the mother and fetus by a multidisciplinary team. Diagnostics and treatment approaches are limited and require individual risk-benefit assessment. Methods In this paper we describe 3 cases of PHPT in pregnant women with different managing approaches (surveillance, drug therapy and surgical treatment) and successful outcomes. Additionally, the most actual literature data on this problem is reviewed. Results The management of PHPT in pregnancy should be based on the clinical features, severity of hypercalcemia, gestational age and patient’s preference. In the first case a conservative approach with low-calcium diet and oral hydration resulted in mother’s reduced serum calcium level before delivery. The second patient had severe hypercalcemia and absolute indications for surgery that was successfully performed at 25 week of gestation. The third woman received cinacalcet because of severe hypercalcemia and potential perioperative risks in the third trimester with an improvement in well-being. Conclusion Nowadays parathyroidectomy is the best choice for patients with symptomatic PHPT and severe hypercalcemia. This intervention should be carried out preferably in the second trimester to avoid maternal and fetal complications. Mild forms of the disease can require just a conservative management. The drug treatment of PHPT during pregnancy is still controversial.


  • Antihypertensive therapy in patients with primary hyperparathyroidism: a single-center retrospective study

    by A.M. Gorbacheva, E.E. Bibik, E.A. Dobreva, A.R. Elfimova, A.K. Eremkina, N.G. Mokrysheva

    Первичный гиперпаратиреоз (ПГПТ) ассоциирован с высокой частотой различных сердечно-сосудистых заболеваний, в частности артериальной гипертензии. На сегодняшний день стратегия выбора антигипертензивной терапии у пациентов с гиперкальциемией не отличается от таковой у пациентов с нормальной сывороточной концентрацией кальция, однако патогенетические механизмы развития артериальной гипертензии при ПГПТ предполагают возможное преимущество в достижении нормотонии при использовании антигипертензивных препаратов определенных групп. ЦЕЛЬ ИССЛЕДОВАНИЯ Изучить спектр антигипертензивных препаратов, применяемых у пациентов с ПГПТ. МАТЕРИАЛ И МЕТОДЫ Исследование проведено на базе ФГБУ «НМИЦ эндокринологии» Минздрава России в период с января 2017 г. по декабрь 2021 г. В исследование вошли пациенты, госпитализированные по поводу верифицированного ПГПТ. Всем пациентам проведено обследование и лечение согласно действующим стандартам оказания медицинской помощи и клиническим рекомендациям. РЕЗУЛЬТАТЫ В исследование включены 585 пациентов с ПГПТ, из них у 397 человек наблюдалась артериальная гипертензия. Пациенты разделены на четыре группы по количеству принимаемых антигипертензивных препаратов: группа А — без терапии, группа В — один препарат, группа С — два препарата, группа D — три препарата и более. Пациенты группы D были статистически значимо старше, имели более низкую скорость клубочковой фильтрации и более высокие показатели кальциемии, чем пациенты группы А. В когорте пациентов 40—55 лет без нарушения функции почек и патологии углеводного обмена данных закономерностей не было выявлено. При анализе лекарственных назначений установлено, что пациентам с артериальной гипертензией требовалась интенсификация лечения и смена антигипертензивных препаратов. ЗАКЛЮЧЕНИЕ В настоящем исследовании продемонстрирована ассоциация между гиперкальциемией и интенсивностью антигипертензивной терапии у пациентов с первичным гиперпаратиреозом, патогенетические основы которой требуют уточнения. Ряд препаратов могут иметь дополнительные преимущества при лечении пациентов с первичным гиперпаратиреозом, однако для верификации этих эффектов необходимы дальнейшие исследования.


  • Structure of metabolic disorders and cardiovascular disease in patients with primary hyperparathyroidism: a single-center retrospective observational study

    by A.M. Gorbacheva, E.E. Bibik, E.A. Dobreva, A.R. Elfimova, A.S. Pushkareva, A.K. Eremkina, N.G. Mokrysheva

    Первичный гиперпаратиреоз (ПГПТ) ассоциирован с большей частотой ряда метаболических и сердечно-сосудистых заболеваний. Оценка распространенности этих нарушений необходима для определения тактики ведения пациентов с ПГПТ. На сегодняшний день такие эпидемиологические данные в мире и в Российской Федерации лимитированы. ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить распространенность и структуру сердечно-сосудистой патологии, нарушений углеводного, липидного и пуринового обмена у пациентов с ПГПТ. МАТЕРИАЛ И МЕТОДЫ Исследование проведено на базе ФГБУ «НМИЦ эндокринологии» Минздрава России в период с января 2017 по декабрь 2021 г. В исследование включены 585 пациентов, госпитализированных по поводу верифицированного ПГПТ. Пациенты распределены в 3 группы в соответствии с возрастом. В группу A (n=119) вошли пациенты от 18 до 49 лет, в группу B (n=297) — пациенты от 50 до 65 лет, в группу C (n=152) — пациенты от 66 лет и старше. Все пациенты обследованы и получили лечение согласно действующим стандартам оказания медицинской помощи и клиническим рекомендациям. РЕЗУЛЬТАТЫ Частота ожирения в исследуемых группах составляла от 17,9 до 36,8%. Повышение концентрации триглицеридов отмечено у 19,7—34,5% пациентов, липопротеинов низкой плотности — у 54,8—73,3%, гиперурикемия выявлена у 47,0—54,1%. Частота сахарного диабета статистически значимо возрастала с увеличением возраста пациентов — от 4,2% у пациентов группы A до 19,1% у пациентов группы C, как и частота артериальной гипертензии (от 29,7 до 94,0% соответственно). У пациентов группы C частота ишемической болезни сердца достигала 21,9%. ЗАКЛЮЧЕНИЕ В настоящем исследовании продемонстрирована высокая частота ряда сердечно-сосудистых заболеваний, а также патологии липидного, углеводного и пуринового обмена у пациентов с первичным гиперпаратиреозом. Однако для принятия клинических решений на основании этих данных необходимы дальнейшие исследования.